Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Luminex Makes Executive Appointments

Fri. June 26, 2009; Posted: 11:44 PM
Stocks RSS
Jun 26, 2009 (Close-Up Media via COMTEX) -- LMNX | Quote | Chart | News | PowerRating -- Luminex Corp., a provider of multiplexed solutions, announced three executive appointments, all effective July 1.

In a release, the company noted the appointments:

Michael F. Pintek has been named Senior Vice President, Operations.

The company said that Pintek is an industry veteran with broad experience in the life science industry. He joins Luminex from Roche, where he has held several positions of increasing responsibility since 2001, most recently as Vice President and General Manager, Blood Screening, Roche Molecular Systems. Prior to Roche, his experience includes positions with Ventana Medical Systems and Abbott Laboratories' Diagnostics Division. Pintek's responsibilities at Luminex will encompass all aspects of the company's operating functions, including sales, marketing, partner management, customer service, technical support, and instrument manufacturing. He will be based at Luminex headquarters in Austin, Texas.

Jeremy Bridge-Cook, Ph.D., has been named Senior Vice President, Assay Group. Dr. Bridge-Cook has previously served as Vice President, Luminex Molecular Diagnostics since Luminex's acquisition of Tm Bioscience in March, 2007. Prior to Luminex, he served in a variety of senior positions at Tm Bioscience since 2001. In his new position, Dr. Bridge-Cook will have responsibility for all of the company's assay and consumables development efforts, including Luminex Molecular Diagnostics, Luminex Bioscience Group, Biothreat, Animal Health, Chemistry R&D, Biology R&D External Research Program, and Emerging Technologies. He will be based at the company's facility in Toronto.

Nancy Krunic, Ph.D., has been named Vice President, Luminex Molecular Diagnostics. Dr. Krunic has previously served as Associate Vice President, Clinical and Regulatory Affairs, Luminex Molecular Diagnostics. Prior to that, she served in a variety of positions at Tm Bioscience since 2004. In her new role, Dr. Krunic will have responsibility for the research, development, and manufacturing of all molecular diagnostics products and strategies for the company. She will be based at the company's facilities in Toronto.

"The board of directors and I are very pleased about these appointments and promotions," said Patrick J. Balthrop, President and Chief Executive Officer of Luminex Corp. "Adding Mike to our management team brings to the company his impressive track record and history of achievement, plus his deep industry experience and knowledge. I am highly confident that Mike will make a significant impact on our business, to the benefit of all of the company's stakeholders.

"Jeremy begins his new position after having made a major contribution heading Luminex Molecular Diagnostics over the past two years. Since the acquisition and integration, his leadership and management skill have been crucial to our success. He also led the significant expansion and investment in our fast-growing molecular diagnostics franchise," continued Balthrop. "Nancy has been a driving force and major leadership presence within Luminex over the past two years. The company has increased our new product development effort under Nancy's leadership, and she has guided the company successfully through the regulatory process for a number of our products across the company. She will continue to drive the company's results in her new position as Vice President of Luminex Molecular Diagnostics."

Luminex Corp. develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries.

((Comments on this story may be sent to health@closeupmedia.com))

For full details on Luminex Corporation (LMNX) click here. Luminex Corporation (LMNX) has Short Term PowerRatings of 5. Details on Luminex Corporation (LMNX) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [LMNX]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.